Welcome to our dedicated page for BriaCell Therapeutics Warrant news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics Warrant stock.
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company based in Los Angeles. They specialize in developing targeted and safe immunotherapy approaches for cancer management, with a current focus on breast cancer. The company has seen success with their patented 'BriaVax' vaccine in FDA Phase I studies, showing promising results. BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology. They are also working on Bria-OTS, personalized immunotherapy for advanced-stage breast cancer.
Rhea-AI Summary
BriaCell Therapeutics Corp. (BCTX) reports significant reduction in metastatic breast cancer tumor behind the eye after 3 cycles of Bria-IMT™ combination regimen. The patient had failed 7 prior regimens, including antibody-drug conjugate therapy, and experienced reduced proptosis and ocular pain. Bria-IMT™ showed robust anti-tumor activity in difficult-to-reach tumors, with a 71% intracranial objective response rate in breast cancer patients with CNS metastases. The pivotal Phase 3 study in advanced breast cancer is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reports 71% intracranial objective response rate (iORR) in advanced breast cancer patients with CNS metastases treated with Bria-IMT™ regimen, demonstrating clinical efficacy and potential market approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen. Overall Survival (OS) data exceeded similar studies, with a median OS up to twice that reported in the literature. Progression Free Survival (PFS) was similar or better than the last regimen in 40% of the patients, and a disease control rate of 40% was observed in evaluable patients, further indicating clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated with Bria-IMT™ in combination with an immune check point inhibitor. The median overall survival was 13.4 months, a marked improvement over the benchmark of 6.7-9.8 months for similar patients. 32 out of 42 patients treated since 2022 remain alive, indicating consistently strong survival benefit. All patients were able to receive therapy with no toxicity-related discontinuations. The Phase 2 study is fully enrolled with 54 advanced metastatic breast cancer patients, showing excellent overall survival and tolerability, as well as a positive immune response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is presenting findings at the 2023 San Antonio Breast Cancer Symposium, demonstrating the effectiveness of their Bria-IMT™ combination regimen in activating cancer-fighting T cells and producing unique antibody responses in patients with disease control. Advanced CD8 ImmunoPET imaging showed the transformation of cold immune suppressed tumors to hot immune responsive ones, indicating the potential of the treatment in cancer patients. The company also plans to present updated overall survival clinical data, showing significant anti-tumor activity of Bria-IMT™ in advanced metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announces a remarkable responder in their Phase 2 study of the Bria-IMT™ combination regimen. A patient with extensive metastatic breast cancer behind the eye experienced a remarkable improvement of eye-bulging 'proptosis' and significant pain reduction after only 3 cycles of treatment. The patient had previously failed 7 regimens and continues to receive treatment. Additional survival updates and clinical data sets will be presented at the San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
Rhea-AI Summary
BriaCell reports unprecedented immune system activation in tumor models with its next generation breast and prostate cancer immunotherapies. The FDA has authorized BriaCell's Investigational New Drug Application (IND) for Bria-OTS™, opening the path to clinical trials. The company's immunotherapies have shown enhanced efficacy and safety profiles, with potential advantages including precision therapy, favorable safety profiles, rapid and cost-effective treatments, and potent immune system activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.41%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) and a new member to its scientific advisory board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary
BriaCell Therapeutics recognizes Breast Cancer Awareness Month and reports positive clinical results in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
Rhea-AI Summary
BriaCell Therapeutics Corp. announces upcoming presentations at scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
FAQ
What is the current stock price of BriaCell Therapeutics Warrant (BCTXW)?
The current stock price of BriaCell Therapeutics Warrant (BCTXW) is $0.335 as of November 22, 2024.
What is BriaCell Therapeutics Corp focused on?
BriaCell is focused on immuno-oncology with the development of safe and targeted approaches for cancer management.
What is the significance of BriaVax vaccine?
BriaVax, a patented vaccine by BriaCell, has shown unprecedented results in FDA Phase I studies for late-stage breast cancer patients.
What upcoming clinical trial is BriaCell preparing for?
BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology to a larger number of breast cancer patients.
What is Bria-OTS and its purpose?
Bria-OTS is an off-the-shelf personalized immunotherapy being developed by BriaCell for the treatment of advanced-stage breast cancer patients by matching their HLA type.
Where is BriaCell Therapeutics Corp headquartered?
BriaCell is headquartered in Los Angeles, California.
How can I contact BriaCell for more information?
You can contact BriaCell through their President & CEO, William V. Williams, at 1-888-485-6340 or email info@briacell.com.
Who is the Media Relations contact for BriaCell?
Jules Abraham from CORE IR serves as the Media Relations contact for BriaCell and can be reached at julesa@coreir.com.
How can investors get in touch with BriaCell?
For investor relations, you can contact CORE IR at investors@briacell.com.
What type of clinical trial is BriaCell conducting for breast cancer?
BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT for metastatic breast cancer patients.
What is BriaCell's outlook on expanding their technology?
While currently focused on breast cancer, BriaCell aims to potentially apply its vaccine technology to other cancer types as well in the future.
BriaCell Therapeutics Corp. Warrant